A seroprevalence study to determine the presence of neutralizing activity and antibodies against Adeno-Associated Virus Vector serotypes in Patients of Duchenne Muscular Dystrophy and patients of Wilson’s disease. - NA

Reliance life sciences0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年9月18日

试验速览

暂无简介。

•1. Patients with known diagnosis of Duchenne Muscular Dystrophy (DMD) or Wilson’s
•2. Patients who are = 5 years of age
•3. Able to understand the study procedures, the risks involved, willing to provide
•written Informed Consent. For patients <18 years of age, parents should be willing
•to provide written informed consent and subject should be willing to give assent for

•4. Inability to comply to the protocol
•5. Patients previously treated with any gene therapy for their disease.
•6. Patients lacking mental capacity to consent to the trial
•7. Seropositive for HIV/HBsAg / HCV (as per previous reports or test conducted prior
•to study enrolment is accepted)
•8. Advanced stage of DMD or Wilson’s disease and / or other comorbidities that are
•likely influence the interpretation of the current study parameter.

发起方

Reliance life sciences